- Q3 revenue increased 41% YoY to $1.119B, Non-GAAP net income rose to $346.7M ($3.29/share vs $2.17 YoY).
- Raised FY2026 INGREZZA net sales guidance to $2.90B–$2.925B (prior $2.825B–$2.875B).
- Lowered FY GAAP SG&A expense outlook to $1.54B–$1.56B while keeping R&D unchanged.
Why is $NBIX moving today? · SEC 8-K archive
$NBIX SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $NBIX: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $NBIX filing catalyst
Why did $NBIX trigger an AI stock catalyst alert?
$NBIX triggered a Stock Catalyst AI alert on 2026-11-02 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.8/10). Headline: Neurocrine Q3 Revenue Jumps 41% to $1.1B, INGREZZA FY Guidance Raised to $2.90B-$2.925B. Key points: - Q3 revenue increased 41% YoY to $1.119B, Non-GAAP net income rose to $346.7M ($3.29/share vs $2.17 YoY). - Raised FY2026 INGREZZA net sales guidance to $2.90B–$2.925B (prior $2.825B–$2.875B). - Lowered FY GAAP SG&A expense outlook to $1.54B–$1.56B while keeping R&D unchanged.
How did $NBIX stock react after the SEC filing?
After the SEC 8-K for $NBIX, observed market reaction: T0 price $145.35. Past moves do not guarantee future results.
Where can I get real-time $NBIX SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $NBIX via Telegram and the VIP Web Terminal from €10/month.